Back to Authors

Sorensen, John M.

A5028595129

Mayo Clinic

Ascenta Therapeutics Inc, Malvern, PA

Citations 2

Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 2531-2531

10.1200/jco.2015.33.15_suppl.2531

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2532-2532

10.1200/jco.2014.32.15_suppl.2532